Jean B. deKernion, MD Chair, Department of Urology The Fran and Ray Stark Professor of Urology Principal Investigator, National Cancer Institute Grant: The Prostate SPORE (Special Program of Research Excellence) at UCLA Location: B7-240 CHS   Phone: 310-206-6453

Educational Background

Professional Memberships

Academic & Medical Staff Appointments

Research & Clinical Interests

Awards & Honors

Additional Information

Selected Bibliography:  

1.                         Rauch MK, Schrage M, Dorey F, deKernion JB, Said J, Reiter RE:  Low P27 protein expression independently predicts poor disease free survival in patients with positive surgical margins following radical prostatectomy. J Urol 161:240, 1999, American Urological Association Annual Meeting, Dallas TX, May 1999

    

2.                         Kattan MW, Witte M, Morton RA, Cangiano T, deKernion J, Eastham JA, Meyer F, Fraded Y:  Validation of a nomogram for predicting disease recurrence following radical prostatectomy for clinically localized prostate cancer.  J Urol 161:329, 1999, American Urological Association Annual Meeting, Dallas TX, May 1999
   

3.                         Zisman A, Pantuck A, deKernion JB, Tso C-L, Belldegrun A:  G250-GM-CSF:  a novel RCC specific tumor vaccine.  American Urological Association Annual Meeting, Atlanta GA, April 2000
   

4.                          Zisman A, Pantuck A, deKernion J, Tso C-L, Belldegrun A:  G250-GM-GSF:  A novel fusion protein serving as a specific tumor vaccine for renal cell carcinoma.  Western Section American Urological Association Annual Meeting, Palm Desert CA, 2000
   

5.                        Wu L, Carey M, Matherly J, Belldegrun AS, deKernion J:  Creating chimeric transcriptional regulatory elements that greatly augment the activity and specificity over the natural prostate specific PSA enhancer.  American Association for Cancer Research Annual meeting, San Francisco CA, April, 2000
   

6.                         Pantuck AJ, Zisman A, Shvarts O, Gitlitz BJ, deKernion JB, Figlin RA, Belldegrun AS:  Natural history and the role of nephrectomy in the biology of RCC:  the UCLA experience.  Proceedings of ASCO 19:343a, 2000, American Society of Clinical Oncology Annual Meeting, New Orleans, LA, May 2000
   

7.                         Pantuck AJ, Zisman A, Chao D, Dorey F, Gitlitz BJ, deKernion JB, Figlin RA, Belldegrun AS:  Regional lymphadenopathy during cytoreductive nephrectomy predicts IL-2 failure in patients with metastatic renal cell carcinoma.  American Society of clinical Oncology Annual Meeeting, 2001
   

8.                          Zisman A, Pantuck AJ, Chao D, Dorey F, Said JW, Gitlitz BJ, deKernion JB, Figlin RA, Belldegrun AS:  Should tumor size cut-off point between RCC Stages T1₁₉₉₇ and T2₁₉₉₇ be lowered?  J Urol 165(5) Supplement:158, 2001.  American Urological Association Annual Meeting, Anaheim CA, June 2001
    

9.                         Zisman A, Pantuck AJ, Chao D, Dorey F, Shvartz O, Gitlitz BJ, deKernion JB, Figlin RA, Belldegrun AS:  Improved prognostication using a novel integrated staging system (UISS) for renal cell carcinoma. J Urol 165(5) Supplement:161, 2001.  American Urological Association Annual Meeting, Anaheim CA, June 2001
   

10.                         Belldegrun AS, Pantuck AJ, Zisman A, Shvarts O, Gitlitz BJ,  deKernion JB, Figlin RA:  Cytoreductive nephrectomy and adjuvant immunotherapy significantly prolong life of patients with metastatic renal cell carcinoma (RCC). J Urol 165(5) Supplement:184, 2001.  American Urological Association Annual Meeting, Anaheim CA, June 2001
    

11.                        Graefen M, Karakiewicz PI, Kattan, deKernion JB, et al:  Cross-cultural assessment of predictors of disease recurrence after radical prostatectomy:  a pooled analysis of 9256 cases. J Urol 165(5) Supplement:353, 2001.  American Urological Association Annual Meeting, Anaheim CA, June 2001
    

12.                         Zisman A, Pantuck AJ, Wieder J, Chao D, Dorey F, Said J, deKernion JB, Figlin RA, Belldegrun A:  Risk group assessment and clinical outcome to predict the natural history of patients with surgically resected renal cell carcinoma.  American Society of Clinical Oncology Annual Meeting, Orlando FL, 2002
    

13.                         Pantuck A, Zisman A, Chao D, Dorey F, deKernion J, Figlin R, Belldegrun A:  A comparison of Interferon versus Interleukin-2 following nephrectomy for metastatic renal cell carcinoma. American Society of Clinical Oncology Annual Meeting, Orlando FL, 2002
    

14.                         Pantuck AJ, Zisman A, Chao D, Dorey F, Flanigan R, deKernion JB, Figlin RA, Belldegrun AS:  Survival advantage of Interleukin-2 over interferon immunotherapy when combined with cytoreductive nephrectomy based on SWOG 8949-matched populations. J Urol 167(4) Supplement: 166, 2002.  American Urological Association Annual Meeting, Orlando FL, May 2002
    

15.                         Zisman A, Pantuck AJ, Chao D, Dorey F, Said JW, Figlin RA, deKernion JB, Belldegrun AS:   Renal cell carcinoma with IVC extension:  the role of nephrectomy, immunotherapy and the relevance of the 1997 TNM staging system. J Urol 167(4) Supplement: 169, 2002.  American Urological Association Annual Meeting, Orlando FL, May 2002
    

16.                         Zisman A, Pantuck AJ, Chao D, Dorey F, Said JW, deKernion JB, Figlin RA, Belldegrun AS:  UISS-based clinical algorithm to predict outcome of patients with localized and advanced renal cell carcinoma. J Urol 167(4) Supplement: 169, 2002.  American Urological Association Annual Meeting, Orlando FL, May 2002
    

17.                        Chen AA, Meng F, Taira RK, Kangarloo H, Churchill BM, deKernion JB Seamless, simultaneous electronic clinical database entry and clinical note generation for prostate cancer: A glimpse into the future of retrospective clinical research and medical documentation.  American Urological Association Annual Meeting, San Antonio, TX, May 2005